Described are stable pre-fusion respiratory syncitial virus (RSV) F polypeptides, immunogenic compositions comprising the polypeptides and uses thereof for the prevention and/or treatment of RSV infection.

Described are stable pre-fusion respiratory syncitial virus (RSV) F polypeptides, immunogenic compositions comprising the polypeptides and uses thereof for the prevention and/or treatment of RSV infection.

The invention relates generally to chimeric viral fusion proteins comprising the ectodomain and optionally the transmembrane domain of a first viral fusion protein (e.g., a spike protein of a coronavirus) and the cytoplasmic domain of a second viral fusion protein (e.g. RSV), immunogenic compositions comprising such chimeric proteins, and methods of use of same.

The invention relates generally to chimeric viral fusion proteins comprising the ectodomain and optionally the transmembrane domain of a first viral fusion protein (e.g., a spike protein of a coronavirus) and the cytoplasmic domain of a second viral fusion protein (e.g. RSV), immunogenic compositions comprising such chimeric proteins, and methods of use of same.

The present disclosure provides a respiratory syncytial virus (RSV) vaccine comprising a messenger RNA (mRNA) comprising an open reading frame (ORF) encoding an RSV F protein antigen, and methods of eliciting an immune response by administering said vaccine.

The present disclosure provides a respiratory syncytial virus (RSV) vaccine comprising a messenger RNA (mRNA) comprising an open reading frame (ORF) encoding an RSV F protein antigen, and methods of eliciting an immune response by administering said vaccine.

Stable pre-fusion respiratory syncytial virus (RSV) F proteins, immunogenic compositions including the proteins and uses thereof for the prevention and/or treatment of RSV infection are described.

Stable pre-fusion respiratory syncytial virus (RSV) F proteins, immunogenic compositions including the proteins and uses thereof for the prevention and/or treatment of RSV infection are described.

The present invention concerns methods of generating CTLs that are able to target at least one antigen from two or more viruses. The method includes exposing mixtures of peptides for different antigens to the same plurality of PBMCs and, at least in certain aspects, expanding the cells in the presence of IL4 and IL7.

Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and/or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.